Francois Sales

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Childhood melanoma ex-blue naevus leading to the identification of a BAP1 tumour predisposition syndrome.

Childhood melanoma ex-blue naevus leading to the identification of a BAP1 tumour predisposition syndrome.

Journal: Pathology
Published: January 31, 2025

Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.

Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.

Journal: Oncotarget
Published: June 03, 2024

Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093.

Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11, 1093.

Journal: Cancers
Published: October 25, 2023

Trocar Site Recurrence after Laparoscopic Cholecystectomy for Unsuspected Isolated Gallbladder Metastasis of Melanoma: A Case Report and Review of the Literature.

Trocar Site Recurrence after Laparoscopic Cholecystectomy for Unsuspected Isolated Gallbladder Metastasis of Melanoma: A Case Report and Review of the Literature.

Journal: Case reports in oncology
Published: September 04, 2023

Corrigendum to 'p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib'[Eur J of Cancer 55 (2016) 98-110].

Corrigendum to 'p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib'[Eur J of Cancer 55 (2016) 98-110].

Journal: European journal of cancer (Oxford, England : 1990)
Published: September 27, 2022

Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value.

Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value.

Journal: Frontiers in oncology
Published: September 21, 2021

Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit.

Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit.

Journal: Molecular cancer research : MCR
Published: December 09, 2020

Recommendations for skin cancer consultation and surgery during COVID-19 pandemic.

Recommendations for skin cancer consultation and surgery during COVID-19 pandemic.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: May 27, 2020

Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial.

Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial.

Journal: European journal of cancer (Oxford, England : 1990)
Published: April 09, 2020

The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma.

The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma.

Journal: Cancers
Published: July 01, 2019

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.

Journal: Oncotarget
Published: February 08, 2018

P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.

P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.

Journal: European journal of cancer (Oxford, England : 1990)
Published: April 19, 2017
Showing 1-12 of 20

Last Updated: 09/26/2026